Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Allergan933 enrolled

Overview

This is an observational study in patients with POAG or OHT that will collect data on the use of Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) in a routine clinical setting. Patients will be seen at baseline and at a follow-up visit approximately 8-12 weeks after baseline, as per normal clinical practice.

Study Type

OBSERVATIONAL

Enrollment

933

Conditions

Open-Angle Glaucoma Ocular Hypertension

Interventions

Bimatoprost 0.01% ophthalmic solutionDRUG

Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of POAG or OHT * Prescribed Lumigan® 0.01% Exclusion Criteria: * None

Locations (1)

Unnamed facility

Ghent, Oost-Vlaanderen, Belgium

Outcomes

Primary Outcomes

Intraocular Pressure (IOP) at Baseline

IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left and right eye at Baseline.

Time frame: Baseline

Intraocular Pressure (IOP) at Week 12

IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the left eye and the right eye at Week 12. The lower the IOP values the greater the improvement.

Time frame: Week 12

Secondary Outcomes

Patient Assessment of Treatment Tolerability Using a 4-Point Scale

Patients evaluated their tolerability of treatment using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed in each of the categories is reported.

Time frame: 12 weeks

Physician Assessment of Treatment Tolerability Using a 4-Point Scale

The Physician evaluated the patient's tolerability of treatment using a 4-point scale (very good, good, moderate, and poor). The number of patients assessed in each of the categories is reported.

Time frame: 12 weeks

Physician Reported Reasons for Treatment Discontinuation

The number of patients who discontinued from treatment by category is reported. More than one reason may apply to each patient.

Time frame: 12 weeks

Number of Patients Continuing Treatment After 12 Weeks

The number of patients continuing treatment after 12 weeks was determined by the physician answering yes to the question: Is the patient continuing on Lumigan® 0.01% treatment?

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.